Navigation Links
NIAID media tip sheet: Annual Meeting of the American Academy of Allergy, Asthma and Immunology

WHAT: The 2010 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) brings together leading allergists and immunologists from around the world.

WHO: Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be presenting their latest research findings at the AAAAI Annual Meeting. For more than 60 years, NIAID has supported allergy and immunology research at U.S. and international institutions and conducted studies within its own laboratories to improve the health of millions of people.

WHEN: February 26 to March 2, 2010

WHERE: Ernest N. Morial Convention Center, New Orleans, La.

Presentation Tips:

Below are advance summaries of select presentations describing NIAID-funded research. The information contained in the summaries is embargoed until the time of presentation.

Findings from the Inner-City Anti-IgE Therapy for Asthma Study

Asthma affects as many as 20 million Americans, but it disproportionately affects childrenespecially African-American and Hispanic childrenwho live in inner-city environments. Over the past two decades, NIAID has supported research programs aimed at developing asthma interventions tailored to children living in inner-city areas. The Inner-City Asthma Consortium (ICAC), a network of eight clinical and two basic research sites nationwide, is a critical part of that effort. ICAC investigators designed and conducted the Inner-City Anti-IgE Therapy for Asthma (ICATA) study in which children with mild to severe asthma were given omalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), an antibody that triggers allergic reactions and inflammation in the lungs. The goal of this study was to determine if adding omalizumab to the asthma treatment directed by the National Asthma Education and Prevention Program Guidelines ( provides additional benefit beyond guidelines-based asthma therapy alone. Three ICAC investigators will discuss the results of the ICATA study and novel insights the study provides regarding the role of allergy in asthma exacerbations.

Title: Symposium: Findings from the Inner-City Anti-IgE Therapy for Asthma (ICATA)
Presenters: William Busse, M.D., University of Wisconsin-Madison
Andrew Liu, M.D., National Jewish Health, Denver
Wayne Shreffler, M.D., Ph.D., Mount Sinai School of Medicine, N.Y.
When: Saturday, Feb. 27, 2010, 12:45 p.m. Central Time
Where: Convention Center, Room B2-2, First Level

Why Bone Abnormalities Occur in People with Rare Immunodeficiency Diseases

Primary immunodeficiency diseases (PIDDs) are caused by inherent defects in the cells of the immune system. Often resulting from inherited genetic defects, PIDDs are marked by an increased susceptibility to infections and other problems that include arthritis and other autoimmune diseases, inflammatory bowel disease, deteriorating lung function, and failure to grow. Hyper-immunoglobulin E syndrome (HIES or Job's syndrome) is a PIDD that affects the immune system and connective tissues. People with HIES can develop boils, lung cysts following pneumonia, and bone abnormalities, such as scoliosis and minimal trauma fractures. In this study, NIAID investigators examined patients with HIES to identify the molecular factors that result in lower-than-normal bone mineral density and an increased number of bone-degrading cells called osteoclasts.

Title: Oral Abstract Session: Immunodeficiency
Presenter: Gulbu Uzel, M.D., NIAID, NIH, Bethesda, Md.
When: Saturday, Feb. 27, 2010, 2:45 p.m. Central Time
Where: Convention Center, Room 206, Second Level

How Distinct Immune Responses Contribute to Different Types of Food Allergy

Eosinophilic gastrointestinal diseases (EGIDs) and conventional peanut allergy both result from abnormal immune responses to foodyet they are distinct disorders. EGIDs are triggered by a food-induced immune response that causes white blood cells known as eosinophils to accumulate in the gut. Eosinophils and inflammation in the tissues result in swelling, which can lead to difficulty swallowing. Peanut allergy is caused by immunoglobulin E (IgE) antibodies, which tell other immune cells to release chemicals. These chemicals, in turn, can cause the symptoms--hives, difficulty breathing and low blood pressure--associated with an allergic reaction. Both EGIDs and peanut allergy are associated with the activation of a type of immune T cell known as a T-helper type 2 (Th2) cell. Th2 cells trigger the IgE production that results in peanut allergy and the increased eosinophil concentrations associated with EGIDs. NIAID investigators will discuss their efforts to understand why the same type of immune cell can trigger these two distinct food allergy disorders.

Title: Oral Abstract Session: Inflammatory Mediators in Allergic Disease
Presenter: Calman Prussin, M.D., NIAID, NIH, Bethesda, Md.
When: Sunday, Feb. 28, 2010, 2:45 p.m. Central Time
Where: Convention Center, Room 220, Second Level

Oral Immunotherapy Reduces the Immune Response to Egg: Results from a Double-Blind, Placebo-Controlled Trial in Egg-Allergic Children

Food allergy is an immunologic disease that affects an estimated 4.7 percent of children under five years of age and 3.7 percent of children ages 5 to 17 years in the United States. NIAID established the Consortium of Food Allergy Research (CoFAR) to develop new approaches to treat and prevent food allergy. In this study, CoFAR investigators tested the safety, efficacy and immunologic effects of using oral immunotherapy to treat children (ages 5 to 18 years) with egg allergy, one of the most common food allergies in this age group. In oral immunotherapy, a person consumes gradually increasing amounts of the food allergen in order to reduce the immune response to the food, thus increasing the ability to tolerate larger amounts of the food. The results of the study indicate a positive clinical effect. The ultimate goal is to develop long-lasting immunologic tolerance so that, even after not eating the food for weeks, the person can eat the food without having an allergic reaction. Results from this and other CoFAR studies will be presented during a press forum at the meeting, which will also be available by live streaming video (accessible at More information about CoFAR may be found at

Title: Late Breaking Oral Abstracts: Clinical Sciences
Presenter: Stacie Jones, M.D., University of Arkansas for Medical Sciences, Little Rock, Ark.
When: Tuesday, Mar. 2, 2010, 2:00 p.m. Central Time
Where: Convention Center, Room R01, Second Level

Title: AAAAI Press Forum: Clinical Research Makes Great Strides in Food Allergy
Presenters: A. Wesley Burks, M.D., Duke University, Durham, N.C.
Hugh Sampson, M.D., Mount Sinai Medical Center, N.Y.
Robert Wood, M.D., Johns Hopkins University, Baltimore
When: Sunday, Feb. 28, 2010, 11:00 a.m. Central Time
Where: Convention Center, Room 224, Second Level

Genetic Variants Associated with Eczema in People of European and African Descent

Atopic dermatitis, also known as eczema, is a chronic skin disorder associated with dry, itchy skin. People with atopic dermatitis can have scaly lesions that can weep clear fluid on their face, neck and hands and are prone to persistent viral and bacterial skin infections. Severe complications of atopic dermatitis include eczema herpeticum, a skin infection due to herpes virus, and eczema vaccinatum, a skin infection due to vaccinia virus, the virus used in the vaccine to prevent smallpox. Investigators participating in NIAID's Atopic Dermatitis and Vaccinia Network (ADVN) are conducting clinical research studies to better understand atopic dermatitis and to identify biomarkers for those at risk for the complications of eczema herpeticum and eczema vaccinatum. This ADVN study describes the role of interferon regulatory factor 2 (IRF2), a protein in immune cells of people with atopic dermatitis that controls the expression of a signaling molecule called interferon-gamma (IFN-γ). The results indicate a genetic association between IRF2 and both atopic dermatitis and eczema herpeticum. Results will be described by the lead author of this study, Pei-Song Gao, M.D., Ph.D., recipient of the 2010 AAAAI Outstanding Pediatric Allergy, Asthma and Immunology Abstract Award. Additional information on ADVN may be found at

Title: Oral Abstract Session: Mechanisms of Atopy
Presenter: Pei-Song Gao, M.D., Ph.D., Johns Hopkins Asthma and Allergy Center, Johns Hopkins University, Baltimore
When: Tuesday, Mar. 2, 2010, 2:45 p.m. Central Time
Where: Convention Center, Room 222, Second Level

What's New in Drugs, Anaphylaxis and Venom

Anaphylaxis is a severe, potentially life-threatening whole-body allergic reaction to certain allergens, including foods, medications and insect bites or stings. After exposure to these substances, an allergic person may experience abdominal pain or cramping, break out into hives or have difficulty breathing. During this session, Dean Metcalfe, M.D., chief of NIAID's Laboratory of Allergic Diseases, will discuss the latest clinical findings concerning the role of mast cells, types of immune cells involved in anaphylaxis and other related allergic disorders and disease. More information on the work in Dr. Metcalfe's lab may be found at

Title: Workshop: Year-in-Review
Presenter: Dean Metcalfe, M.D., NIAID, NIH, Bethesda, Md.
When: Tuesday, Mar. 2, 2010, 3:55 p.m. Central Time
Where: Convention Center, Rooms R02 and R03, Second Level

More information about the press events that will be held at the AAAAI Annual Meeting may be found at


Contact: Julie Wu
NIH/National Institute of Allergy and Infectious Diseases

Related medicine news :

1. NIAID announces new human immunology research awards to help fight emerging infectious diseases
2. NIAID announces vaccine adjuvant discovery contracts
3. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
4. NIAID launches 2009 H1N1 influenza vaccine trial in pregnant women
5. NIAID funds clinical trials that address the problem of antimicrobial resistance
6. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
7. NIAID to fund new human immune profiling research centers
8. NIAID media availability: Still searching for predictors of asthma attacks
9. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
10. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
11. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: